CSA Biotechnologies
Fighting Antimicrobial Resistance with First-in-Class Technology
Pioneering the Fight Against AMR
CSA Biotechnologies was founded in 2012 with a singular mission: to develop novel antimicrobial therapies that can effectively combat the growing threat of antimicrobial resistance (AMR).
Our technology platform is based on Ceragenins - a class of synthetic molecules that mimic the body's natural antimicrobial peptides while offering improved stability and manufacturability.
With over two decades of research and development, we have built a robust pipeline of drug candidates targeting high unmet medical needs, from diabetic foot ulcers to serious fungal infections.
Today, we continue to advance our clinical programs while making our technology available through our veterinary product line, bringing the benefits of Ceragenin science to animal health.
Research Begins
Initial research into antimicrobial peptide mimics begins at Brigham Young University
Company Founded
CSA Biotechnologies established to commercialize Ceragenin technology
Veterinary Launch
Ceragyn product line launched for animal health applications
Clinical Progress
Lead candidate CSA-144 advances to Phase 1 clinical trials
Expanding Pipeline
Multiple programs across dermatology, women's health, and antifungal indications
Our Team
Meet the leaders driving innovation in antimicrobial therapeutics.
Jace Sanders, MBA
Chief Financial Officer
Jace has been with CSA Biotech since 2012. He earned an MBA from Utah State University in 2003 and has worked in finance and business development since. He's been instrumental in the development, management, and funding of dozens of small businesses.
Michelle Higgin, PhD
Chief Development Officer
She began her Pharmaceutical career 20 years ago when she started working in the labs at Johnson and Johnson in Raritan, N.J. Since then, she's held a wide range of positions and focused her expertise on high level project management for virtual biotech companies. Dr. Higgin leads full IND-enabling programs as well as nonclinical and CMC programs during clinical development.
Research Partners
We collaborate with leading academic institutions worldwide to advance Ceragenin research and development.
Our research partnerships span prestigious institutions including BYU, Johns Hopkins, UC Berkeley, University of Pennsylvania, and many more worldwide.
Mission & Values
“To develop and deliver innovative antimicrobial therapies that save lives and improve outcomes for patients worldwide, while addressing the critical global challenge of antimicrobial resistance.”
Mission-Driven
We are committed to combating antimicrobial resistance and improving patient outcomes through innovative science.
Innovation
We continuously push the boundaries of antimicrobial research to develop first-in-class therapies.
Collaboration
We work closely with academic institutions, healthcare providers, and industry partners to advance our mission.
Integrity
We uphold the highest standards of scientific rigor, ethical conduct, and transparency in all we do.
Corporate Information
Company Details
CSA Biotechnologies LLC
2012
Biotechnology Research
Clinical Stage
Locations
Queen Creek, Arizona
Queen Creek, Arizona
3298 N Main St, Spanish Fork, UT 84660-8501